XML 57 R45.htm IDEA: XBRL DOCUMENT v3.24.1.u1
USE OF SPECIAL PURPOSE ENTITIES AND VARIABLE INTEREST ENTITIES - Condensed Consolidated Balance Sheets (Details) - USD ($)
Mar. 31, 2024
Dec. 31, 2023
Mar. 31, 2023
Dec. 31, 2022
ASSETS        
Cash, cash equivalents and restricted cash $ 64,645,554 $ 51,517,192 $ 100,518,930 $ 47,366,365
Accrued interest receivable [1] 8,463,278 8,588,805    
Investment related receivable [1] 17,320,000 0    
Loans held for investment, net of allowance for credit losses 1,285,478,916 [1] 1,383,881,197 [1]   1,071,889,518
Total assets [1] 1,378,191,925 1,446,932,447    
LIABILITIES        
Accrued interest payable [1] 3,850,616 4,092,701    
Collateralized loan obligations and secured financings [1] 1,075,890,203 1,146,210,752    
Total liabilities [1] 1,135,256,623 1,206,140,067    
Equity 242,935,302 [1] 240,792,380 [1] $ 240,847,239 $ 243,001,497
Total liabilities and equity [1] 1,378,191,925 1,446,932,447    
2021-FL1 CLO and LMF 2023-1        
ASSETS        
Cash, cash equivalents and restricted cash 72,845 270,217    
Other receivable 61,734 0    
Accrued interest receivable 8,248,978 8,588,805    
Investment related receivable 17,320,000 0    
Loans held for investment, net of allowance for credit losses 1,285,718,344 1,375,277,312    
Total assets 1,311,421,901 1,384,136,334    
LIABILITIES        
Accrued interest payable 3,754,453 3,996,538    
Collateralized loan obligations and secured financings 1,075,890,203 1,146,210,752    
Total liabilities 1,079,644,656 1,150,207,290    
Equity 231,777,245 233,929,044    
Total liabilities and equity $ 1,311,421,901 $ 1,384,136,334    
[1] Our consolidated balance sheets include assets and liabilities of consolidated variable interest entities ("VIEs") as the Company was the primary beneficiary of these VIEs. As of March 31, 2024 and December 31, 2023, assets of consolidated VIEs totaled $1,311,421,901 and $1,384,136,334, respectively and the liabilities of consolidated VIEs totaled $1,079,644,656 and $1,150,207,290 respectively. See Note 4 for further discussion.